(19)
(11) EP 2 791 135 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
18.07.2018 Bulletin 2018/29

(45) Mention of the grant of the patent:
06.06.2018 Bulletin 2018/23

(21) Application number: 12857224.5

(22) Date of filing: 11.12.2012
(51) International Patent Classification (IPC): 
C07D 451/02(2006.01)
A61P 25/00(2006.01)
A61K 31/46(2006.01)
(86) International application number:
PCT/US2012/068943
(87) International publication number:
WO 2013/090260 (20.06.2013 Gazette 2013/25)

(54)

ANABASINE DERIVATIVES TARGETING THE NICOTINIC ACETYLCHOLINE RECEPTORS

AUF NIKOTINISCHE ACETYLCHOLINREZEPTOREN GERICHTETE ANABASINDERIVATE

DÉRIVÉS D'ANABASINE CIBLANT LES RÉCEPTEURS NICOTINIQUES DE L'ACÉTYLCHOLINE


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 12.12.2011 US 201161569539 P

(43) Date of publication of application:
22.10.2014 Bulletin 2014/43

(73) Proprietor: KemPharm Consulting Inc.
Gainesville FL 32605 (US)

(72) Inventors:
  • KEM, William, Reade
    Gainesville, FL 32605-3454 (US)
  • SOTI, Ferenc
    Gainesville, FL 32601-8521 (US)
  • XING, Hong
    Gainesville, FL 32605 (US)

(74) Representative: Helbig, Christian 
Wagner + Helbig Patentanwälte Pfarrstrasse 14
80538 München
80538 München (DE)


(56) References cited: : 
WO-A1-92/01688
WO-A1-2008/095944
WO-A1-2006/133303
WO-A2-01/23385
   
  • SLAVOV S H ET AL: "A computational study of the binding of 3-(arylidene) anabaseines to two major brain nicotinic acetylcholine receptors and to the acetylcholine binding protein", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 45, no. 6, 1 June 2010 (2010-06-01), pages 2433-2446, XP027013913, ISSN: 0223-5234 [retrieved on 2010-02-13]
  • HASHIMOTO K ET AL: "ALPHA.7 NICOTINIC RECEPTOR AGONISTS AS POTENTIAL THERAPEUTIC DRUGS FOR SCHIZOPHRENIA", CENTRAL NERVOUS SYSTEM AGENTS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS LTD., BUSSUM, NL, vol. 5, no. 3, 1 January 2005 (2005-01-01) , pages 171-184, XP009074846, ISSN: 1871-5249
  • ANTOINE TALY ET AL: "Discrimination of agonists versus antagonists of nicotinic ligands based on docking onto AChBP structures", JOURNAL OF MOLECULAR GRAPHICS AND MODELLING, ELSEVIER SCIENCE, NEW YORK, NY, US, vol. 30, 22 June 2011 (2011-06-22), pages 100-109, XP028272492, ISSN: 1093-3263, DOI: 10.1016/J.JMGM.2011.06.008 [retrieved on 2011-06-29]
  • SVETOSLAV H. SLAVOV ET AL.: 'A computational study of the binding of 3-(aryl idene) anabaseines to two major brain nicotinic acetylcholine receptors and to the acetylcholine binding protein.' EUROPEAN JOURNAL OF MEDICINAL CHEMIST .Y. vol. 45, no. 6, June 2010, pages 2433 - 2446, XP027013913
  • KENJI HASHIMOTO ET AL.: 'alpha7 Nicotinic Agonists as Potential Therapeutic Drugs for Schizophrenia.' CURRENT MEDICINAL CHEMISTRY-CENTRAL NERVOUS SYSTEM AGENTS. vol. 5, no. 3, September 2005, pages 171 - 184, XP009074846
  • NATALE BELLUARDO ET AL.: 'Central nicotinic receptors, neurotrophic factors and neuroprotection.' BEHAVIOURAL BRAIN RESEARCH. vol. 113, no. 1-2, August 2000, pages 2 1 - 34, XP055156520
  • ALEXANDER HOEPPING ET AL.: 'Novel Conformationally Constrained Tropane Analo gues by 6-endo-trig Radical Cyclization and Stille Coupling, Switch of Activity toward the serotonin and/or Norepinephrine Transporter.' JOURNAL OF M EDICINAL CHEMISTRY. vol. 43, no. 10, 18 May 2000, pages 2064 - 2071, XP002169501
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).